Hodgkin Lymphoma: The Latest in Treatment and Research
Chemotherapy has been the backbone of treatment for both untreated and relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL). But treatment paradigms for cHL are changing. Immunotherapies that unmask cancer cells and make them vulnerable to our immune system, called immune checkpoint inhibitors (ICIs), were recently approved for relapsed and refractory cHL. Examples include PD-1 inhibitors such … Read more